T. Rowe Price Associates
IRWD icon

T. Rowe Price Associates’s Ironwood Pharmaceuticals IRWD Stock Holding History

T. Rowe Price Associates’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$437K Buy
124,314
+24,951
+25% +$102K ﹤0.01% 2517
2025
Q4 		$335K Buy
99,363
+19,185
+24% +$49.8K ﹤0.01% 2593
2025
Q3 		$106K Sell
80,178
-92,343
-54% -$95.6K ﹤0.01% 2910
2025
Q2 		$123K Buy
172,521
+1,243
+0.7% +$976 ﹤0.01% 2853
2025
Q1 		$252K Buy
171,278
+75,380
+79% +$180K ﹤0.01% 2536
2024
Q4 		$425K Sell
95,898
-7,458
-7% -$30.3K ﹤0.01% 2353
2024
Q3 		$426K Buy
103,356
+1,908
+2% +$10.3K ﹤0.01% 2328
2024
Q2 		$662K Buy
101,448
+15,871
+19% +$112K ﹤0.01% 2069
2024
Q1 		$746K Buy
85,577
+4,993
+6% +$60.6K ﹤0.01% 2037
2023
Q4 		$922K Buy
80,584
+8,477
+12% +$83.9K ﹤0.01% 1905
2023
Q3 		$695K Buy
72,107
+10,762
+18% +$105K ﹤0.01% 1963
2023
Q2 		$653K Buy
61,345
+1,551
+3% +$16.7K ﹤0.01% 2011
2023
Q1 		$630K Sell
59,794
-32,901
-35% -$369K ﹤0.01% 2010
2022
Q4 		$1.15M Sell
92,695
-7,694
-8% -$87.3K ﹤0.01% 1698
2022
Q3 		$1.04M Buy
100,389
+8,992
+10% +$102K ﹤0.01% 1727
2022
Q2 		$1.05M Sell
91,397
-153
-0.2% -$1.8K ﹤0.01% 1874
2022
Q1 		$1.15M Sell
91,550
-6,067
-6% -$69.5K ﹤0.01% 1929
2021
Q4 		$1.14M Sell
97,617
-24,528
-20% -$301K ﹤0.01% 1962
2021
Q3 		$1.59M Sell
122,145
-10,700
-8% -$138K ﹤0.01% 1829
2021
Q2 		$1.71M Sell
132,845
-18,069
-12% -$207K ﹤0.01% 1805
2021
Q1 		$1.69M Sell
150,914
-22,160
-13% -$234K ﹤0.01% 1798
2020
Q4 		$1.97M Sell
173,074
-787,084
-82% -$8.61M ﹤0.01% 1643
2020
Q3 		$8.64M Sell
960,158
-64,134
-6% -$637K ﹤0.01% 1327
2020
Q2 		$10.6M Sell
1,024,292
-201,831
-16% -$2.07M ﹤0.01% 1288
2020
Q1 		$12.4M Buy
1,226,123
+59,308
+5% +$697K ﹤0.01% 1192
2019
Q4 		$15.5M Sell
1,166,815
-4,067
-0.3% -$44.8K ﹤0.01% 1237
2019
Q3 		$10.1M Buy
1,170,882
+16,838
+1% +$164K ﹤0.01% 1290
2019
Q2 		$12.6M Sell
1,154,044
-1,475,001
-56% -$16.5M ﹤0.01% 1277
2019
Q1 		$29.8M Sell
2,629,045
-1,061,830
-29% -$11.9M ﹤0.01% 1048
2018
Q4 		$32M Sell
3,690,875
-6,964,363
-65% -$79.9M 0.01% 982
2018
Q3 		$165M Sell
10,655,238
-2,680,060
-20% -$42.4M 0.02% 535
2018
Q2 		$214M Sell
13,335,298
-1,243,980
-9% -$18.4M 0.03% 460
2018
Q1 		$188M Sell
14,579,278
-6,750,018
-32% -$84.1M 0.03% 472
2017
Q4 		$268M Buy
21,329,296
+1,078,471
+5% +$14.1M 0.04% 394
2017
Q3 		$267M Buy
20,250,825
+638,103
+3% +$8.78M 0.05% 385
2017
Q2 		$310M Buy
19,612,722
+142,710
+0.7% +$2.07M 0.06% 341
2017
Q1 		$278M Buy
19,470,012
+2,170,059
+13% +$29.7M 0.05% 355
2016
Q4 		$222M Buy
17,299,953
+6,827,507
+65% +$86.2M 0.04% 405
2016
Q3 		$139M Buy
10,472,446
+1,515,556
+17% +$17.7M 0.03% 501
2016
Q2 		$98.1M Buy
8,956,890
+950,869
+12% +$9.29M 0.02% 569
2016
Q1 		$73.4M Buy
8,006,021
+1,895,117
+31% +$15.6M 0.02% 649
2015
Q4 		$59.3M Sell
6,110,904
-13,492
-0.2% -$130K 0.01% 707
2015
Q3 		$53.4M Sell
6,124,396
-72,106
-1% -$673K 0.01% 752
2015
Q2 		$62.6M Buy
6,196,502
+3,055,986
+97% +$35.5M 0.01% 759
2015
Q1 		$42.1M Buy
3,140,516
+1,981,596
+171% +$26M 0.01% 894
2014
Q4 		$14.9M Sell
1,158,920
-532,621
-31% -$6.1M ﹤0.01% 1216
2014
Q3 		$18.4M Sell
1,691,541
-35,820
-2% -$410K ﹤0.01% 1141
2014
Q2 		$22.2M Sell
1,727,361
-477,642
-22% -$5.19M ﹤0.01% 1098
2014
Q1 		$22.8M Sell
2,205,003
-146,525
-6% -$1.65M 0.01% 1073
2013
Q4 		$22.9M Buy
2,351,528
+312,892
+15% +$2.81M 0.01% 1066
2013
Q3 		$20.2M Buy
2,038,636
+113,789
+6% +$1.12M 0.01% 1075
2013
Q2 		$16M Buy
+1,924,847
New +$23.3M ﹤0.01% 1134

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's IRWD Position: Q1 2026 in Review

T. Rowe Price Associates increased its Ironwood Pharmaceuticals (IRWD) stake by 25% in Q1 2026, buying an estimated $102K and bringing the position to 124,314 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #2517.

T. Rowe Price Associates first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $310M in Q2 2017. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • T. Rowe Price Associates held 124,314 shares of Ironwood Pharmaceuticals worth $437K as of Q1 2026.
  • T. Rowe Price Associates bought 24,951 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $102K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2517 holding.
  • T. Rowe Price Associates first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Ironwood Pharmaceuticals position peaked at $310M in Q2 2017.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.